

**Request for Prior Authorization for Filspari (sparsentan)**  
**Website Form – [www.highmarkhealthoptions.com](http://www.highmarkhealthoptions.com)**  
**Submit request via: Fax - 1-855-476-4158**

All requests for Filspari (sparsentan) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

**Prior Authorization Criteria:**

Coverage may be provided with a diagnosis of **primary immunoglobulin A nephropathy (IgAN)** and the following criteria is met:

- Must be prescribed by or in consultation with a nephrologist
- Diagnosis has been confirmed by biopsy
- Must have an estimated glomerular filtration rate  $\geq 30$  ml/min/1.73m<sup>2</sup>
- Must have a total urine protein  $\geq 1.0$  g/day
- Must be at risk of rapid disease progression defined as having a urine protein-to-creatinine ratio (UPCR)  $\geq 1.5$  g/g
- Must have tried maximum tolerated dose of a renin-angiotensin system (RAS) inhibitor treatment [i.e. angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB)] or had an intolerance or contraindication to RAS inhibitor treatment.
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Must be age-appropriate according to FDA-approved labeling, nationally recognized compendia, or evidence-based practice guidelines
- **Initial Duration of Approval:** 6 months
- **Reauthorization criteria**
  - Decrease from baseline in total urine protein or UPCR
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

Drugs are authorized in generic form unless the branded product is on the preferred drug list or the prescriber has indicated in writing that the branded product is medically necessary. If only the branded product is on the preferred drug list, the generic form will be considered non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.

**FILSPARI (SPARSENTAN)  
PRIOR AUTHORIZATION FORM**

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. **FAX: (855) 476-4158**

If needed, you may call to speak to a Pharmacy Services Representative. **PHONE: (844) 325-6251 Mon – Fri 8:00 am to 7:00 pm**

**PROVIDER INFORMATION**

Requesting Provider:	NPI:
Provider Specialty:	Office Contact:
Office Address:	Office Phone:
	Office Fax:

**MEMBER INFORMATION**

Member Name:	DOB:
Member ID:	Member weight:      Height:

**REQUESTED DRUG INFORMATION**

Medication:	Strength:
Directions:	Quantity:      Refills:
Is the member currently receiving requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No      Date Medication Initiated:	
Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No	

**Billing Information**

This medication will be billed: <input type="checkbox"/> at a pharmacy <b>OR</b> <input type="checkbox"/> medically, JCODE: _____
Place of Service: <input type="checkbox"/> Hospital <input type="checkbox"/> Provider's office <input type="checkbox"/> Member's home <input type="checkbox"/> Other

**Place of Service Information**

Name:	NPI:
Address:	Phone:

**MEDICAL HISTORY (Complete for ALL requests)**

Diagnosis:	ICD Code:
Has the diagnosis been confirmed by biopsy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
What is the estimated glomerular filtration rate? _____	
What is the total urine protein? _____	
What is the urine protein-to-creatinine ration (UPCR)? _____	
Is the member currently stable on renin-angiotensin system (RAS) inhibitor treatment (ie. ACE or ARB) <input type="checkbox"/> Yes, please list below <input type="checkbox"/> No	

**CURRENT or PREVIOUS THERAPY**

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

**REAUTHORIZATION**

Has the member experienced an improvement with treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No
Which of the following have improved and what is the current level? <input type="checkbox"/> Total urine protein _____ <input type="checkbox"/> Urine protein-to-creatinine ration (UPCR)? _____

**SUPPORTING INFORMATION or CLINICAL RATIONALE**


<b>Prescribing Provider Signature</b>	<b>Date</b>